Close Menu

As second-generation sequencers from Roche/454, Illumina, and Life Technologies compete for targeted sequencing market share, researchers at the Scripps Research Institute and the J. Craig Venter Institute recently published an evaluation of the three platforms for this application.

The two teams, which used versions of the platforms that have since been updated, found they each suffered from non-uniform coverage and inherent systematic errors, making it difficult to use data from different platforms for the same study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.